Meeks is the Edward M. Schaeffer, MD, PhD Professor of Urology and associate professor of urology, biochemistry, and molecular genetics at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
The phase 1/2 ResQ133A-NMIBC trial (NCT06800963) is evaluating intravesical recombinant BCG in patients with BCG-naïve high-risk NMIBC across US sites, with safety as the primary end point and complete response and disease-free survival as secondary end points, building on European data showing 50% response rates and no dose-limiting toxicities in BCG-unresponsive disease.
Joshua J. Meeks, MD, PhD, discussed the emerging role of ctDNA in guiding adjuvant and neoadjuvant strategies in patients with bladder cancer.
Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.
The final segment discusses operational and logistical impacts, including workflow efficiency, staff training, and reimbursement considerations for subcutaneous immunotherapy.
Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.
This section explores how subcutaneous delivery can improve patient satisfaction, adherence, and quality of life through reduced treatment times and greater convenience.
The segment reviews clinical trial outcomes and real-world findings on subcutaneous immunotherapy, focusing on efficacy, safety, and its practical application in daily urology practice.
This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience.
This segment outlines how immune checkpoint inhibitors have become essential in bladder cancer management, examining their roles across treatment lines and the current standards of care.
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC.
"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.
"There really wasn't a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD.
“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD.
December 5th 2025
